Prime MedicinePRME
PRME
About: Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Employees: 214
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
22% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 32
12% more funds holding
Funds holding: 116 [Q3] → 130 (+14) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
8.19% less ownership
Funds ownership: 57.24% [Q3] → 49.05% (-8.19%) [Q4]
29% less capital invested
Capital invested by funds: $266M [Q3] → $188M (-$77.9M) [Q4]
56% less call options, than puts
Call options by funds: $243K | Put options by funds: $553K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
706%
upside
Avg. target
$12
868%
upside
High target
$16
1,190%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Geulah Livshits 7% 1-year accuracy 4 / 60 met price target | 1,190%upside $16 | Buy Maintained | 20 Mar 2025 |
HC Wainwright & Co. Arthur He 6% 1-year accuracy 2 / 33 met price target | 706%upside $10 | Buy Reiterated | 19 Mar 2025 |
Citizens Capital Markets Silvan Tuerkcan 20% 1-year accuracy 10 / 51 met price target | 706%upside $10 | Market Outperform Reiterated | 4 Mar 2025 |
Financial journalist opinion
Positive
The Motley Fool
4 weeks ago
Why Prime Medicine Stock Was Climbing Higher This Week
News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening.
Positive
The Motley Fool
1 month ago
Why Prime Medicine Stock Is Soaring Today
Shares of Prime Medicine (PRME 12.50%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.
Neutral
GlobeNewsWire
1 month ago
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP --
Neutral
GlobeNewsWire
1 month ago
Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates
-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1H 2026 -- -- Additional high-value programs advancing through preclinical development -- CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2024 and provided a business update.
Neutral
GlobeNewsWire
1 month ago
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D.
Neutral
PRNewsWire
2 months ago
Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm
NEW YORK , Jan. 30, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prime Medicine, Inc. (NASDAQ: PRME) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Positive
Seeking Alpha
4 months ago
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies
Prime Medicine's proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME's pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson's Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 million in cash upfront, a $55 million equity stake, $3.5B in potential milestone payments, and diversification into ex vivo T-cell therapies.
Neutral
GlobeNewsWire
4 months ago
Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Wilson Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. "Wilson Disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson Disease pipeline landscape is provided which includes the disease overview and Wilson Disease treatment guidelines. The assessment part of the report embraces, in depth Wilson Disease commercial assessment and clinical assessment of the pipeline products under development.
Neutral
GlobeNewsWire
5 months ago
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences:
Positive
The Motley Fool
5 months ago
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century.
Charts implemented using Lightweight Charts™